141 related articles for article (PubMed ID: 34629893)
1. Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease.
Figueroa JM; Lombardo ME; Dogliotti A; Flynn LP; Giugliano R; Simonelli G; Valentini R; Ramos A; Romano P; Marcote M; Michelini A; Salvado A; Sykora E; Kniz C; Kobelinsky M; Salzberg DM; Jerusalinsky D; Uchitel O
Int J Gen Med; 2021; 14():6277-6286. PubMed ID: 34629893
[TBL] [Abstract][Full Text] [Related]
2. A study protocol for a double-blind randomised placebo-controlled trial evaluating the efficacy of carrageenan nasal and throat spray for COVID-19 prophylaxis-ICE-COVID.
Jessop ZM; Gibson J; Lim JY; Jovic TH; Combellack E; Dobbs TD; Carter K; Hiles S; Islam S; Healy B; Humphreys I; Eccles R; Hutchings HA; Whitaker IS
Trials; 2022 Sep; 23(1):782. PubMed ID: 36109791
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
4. Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold.
Fazekas T; Eickhoff P; Pruckner N; Vollnhofer G; Fischmeister G; Diakos C; Rauch M; Verdianz M; Zoubek A; Gadner H; Lion T
BMC Complement Altern Med; 2012 Sep; 12():147. PubMed ID: 22950667
[TBL] [Abstract][Full Text] [Related]
5. Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trial.
Grau-Pujol B; Camprubí D; Marti-Soler H; Fernández-Pardos M; Guinovart C; Muñoz J
Trials; 2020 Jul; 21(1):688. PubMed ID: 32727613
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold.
Eccles R; Meier C; Jawad M; Weinmüllner R; Grassauer A; Prieschl-Grassauer E
Respir Res; 2010 Aug; 11(1):108. PubMed ID: 20696083
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial.
Eccles R; Winther B; Johnston SL; Robinson P; Trampisch M; Koelsch S
Respir Res; 2015 Oct; 16():121. PubMed ID: 26438038
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of a carrageenan nasal spray in patients with common cold: a randomized controlled trial.
Ludwig M; Enzenhofer E; Schneider S; Rauch M; Bodenteich A; Neumann K; Prieschl-Grassauer E; Grassauer A; Lion T; Mueller CA
Respir Res; 2013 Nov; 14(1):124. PubMed ID: 24219370
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
10. Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials.
Koenighofer M; Lion T; Bodenteich A; Prieschl-Grassauer E; Grassauer A; Unger H; Mueller CA; Fazekas T
Multidiscip Respir Med; 2014; 9(1):57. PubMed ID: 25411637
[TBL] [Abstract][Full Text] [Related]
11. A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial.
García IG; Rodriguez-Rubio M; Mariblanca AR; de Soto LM; García LD; Villatoro JM; Parada JQ; Meseguer ES; Rosales MJ; González J; Arribas JR; Carcas AJ; de la Oliva P; Borobia AM
Trials; 2020 Jun; 21(1):466. PubMed ID: 32493475
[TBL] [Abstract][Full Text] [Related]
12. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of iota-carrageenan nasal spray in treatment and prevention of the common cold.
Bichiri D; Rente AR; Jesus Â
Med Pharm Rep; 2021 Jan; 94(1):28-34. PubMed ID: 33629045
[TBL] [Abstract][Full Text] [Related]
15. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
16. Carrageenan nasal spray may double the rate of recovery from coronavirus and influenza virus infections: Re-analysis of randomized trial data.
Hemilä H; Chalker E
Pharmacol Res Perspect; 2021 Aug; 9(4):e00810. PubMed ID: 34128358
[TBL] [Abstract][Full Text] [Related]
17. The antiviral activity of iota-, kappa-, and lambda-carrageenan against COVID-19: A critical review.
Frediansyah A
Clin Epidemiol Glob Health; 2021; 12():100826. PubMed ID: 34222718
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II).
Ye Q; Wang H; Xia X; Zhou C; Liu Z; Xia ZE; Zhang Z; Zhao Y; Yehenala J; Wang S; Zhou G; Hu K; Wu B; Wu CT; Wang S; He Y
Trials; 2020 Jun; 21(1):520. PubMed ID: 32532356
[TBL] [Abstract][Full Text] [Related]
19. Low Acyl Gellan as an Excipient to Improve the Sprayability and Mucoadhesion of Iota Carrageenan in a Nasal Spray to Prevent Infection With SARS-CoV-2.
Robinson TE; Moakes RJA; Grover LM
Front Med Technol; 2021; 3():687681. PubMed ID: 35047933
[TBL] [Abstract][Full Text] [Related]
20. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
